Sector revisions Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 00:00:00 18/06/2026 +04			5-day change	1st Jan Change
2.980 ^USD	+1.71%		+1.02%	+8.36%

06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	4m. EPS revision	1y. EPS revision	Visibility	Nbr of analysts
PERSPECTIVE THERAPEUTICS, INC.				15
LONZA GROUP AG				23
REVOLUTION MEDICINES, INC.				21
IQVIA HOLDINGS INC.				19
BEONE MEDICINES AG				27
CELLTRION, INC.				24
ASCENDIS PHARMA A/S	-	-		18
MEDPACE HOLDINGS, INC.				12
EUROFINS SCIENTIFIC SE				14
IONIS PHARMACEUTICALS, INC.				23
ICON PUBLIC LIMITED COMPANY				16
TEMPUS AI, INC.				15
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.				15
BIO-TECHNE CORPORATION				13
BLUEPRINT MEDICINES CORPORATION			-	-
ABIVAX				6
QIAGEN N.V.				14
ALKERMES PLC				16
KYMERA THERAPEUTICS, INC.				21
Average				17
Weighted average by Cap.				20